First-in-Human trial tests gene therapy for blinding eye disease
NCT ID NCT06292650
Summary
This is the first study in people to test the safety and early effects of an experimental gene therapy called ZM-02 for retinitis pigmentosa (RP), an inherited disease that causes progressive vision loss. About 12 adults with RP will receive either a single injection of the therapy or a sham injection into one eye. The main goal is to see if the treatment is safe and well-tolerated, while also checking for any early signs that it might help preserve or improve vision.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RETINITIS PIGMENTOSA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Locations
-
Beijing Tongren Hospital of Capital Medical University
RECRUITINGBeijing, Beijing Municipality, China
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact
Conditions
Explore the condition pages connected to this study.